bioAffinity closes $1.45M capital raise and reclassifies warrants adding $2.8M to equity

bioAffinity Technologies, Inc.

• Private placement of 990 Series B Preferred shares convertible into ~4.3M common at $0.23/sh and warrants for ~6.7M shares at $0.352/sh, gross proceeds ~$1.2M.
• Warrant inducement: existing warrants exercised at reduced $0.23/sh for $253K cash; new warrants for 1.43M shares at $0.352/sh pending stockholder approval.
• Warrant amendment reclassifies May 2025 warrants from liability to equity, increasing stockholders' equity by ~$2.8M.
• Anti-dilution adjustment on May 2025 warrants reduces exercise price to $0.23/sh and increases shares issuable by ~8M.
• Authorized common shares increased from 100M to 350M.